Study Details
Observing Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease
(IRB#: IRB_00190017)
This study will collect data from patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) to better understand the disease and the effects of treprostinil treatment. People in the study will be in one of three groups. One group will not be receiving the treatment. One group will have initiated treatment within the previous 60 days before participation. Another group will already be receiving the treatment and have been taking it for more than 60 days. People in the study will have data collected at the beginning of the study. At a one-time 3-month check-in, and every 6 months for 5 years.
- All genders
- Over 18 years old
- Volunteers with special conditions
- In Person
- Paid
Who can participate?
Gender: All genders
Age: Over 18 years old
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages18 years and older
- Diagnosis of Interstitial Lung Disease (ILD)
- Diagnosis of Pulmonary Hypertension (PH)
- Able to attend in person visits
Exclusion Criteria
- Patients receiving Yutrepia (inhaled treprostinil)
Will I be paid for my time?
Yes
IRB#: IRB_00190017
PI: Emily Beck
Department: PULMONARY
Approval Date: 2025-11-12 18:00:00
Specialties: Pulmonary
I am Interested